Amplification of the ERBB2 gene (encoding for HER2 protein) is detected by fluorescent in
situ hybridization (FISH) in human breast and esophagogastric cancer tissue specimens.
PD-L1 IHC 22C3 is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein. PD-L1 IHC 22C3 is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).
Ki67 is a nuclear protein expressed in proliferating cells, which is detected by a primary monoclonal rabbit anti-human Ki67 antibody (clone 30-9). Ki67 expression level is determined by the percentage of appropriately stained tumor cells.
Consultation by a Genoptix Hematopathologist on previously diagnosed cases. We require appropriate clinical data and slides, as well as the most recent morphology report and laboratory test results.
When serial or subsequent COMPASS® evaluations are requested on the same patient and deemed clinically appropriate by a Genoptix Hematopathologist, Genoptix will automatically provide a CHART® report, unless otherwise indicated by the ordering physician. CHART® includes all medically necessary technologies, and a consultative review and correlation with relevant prior findings and intervening treatment by a Genoptix Hematopathologist.
The client’s pathologist must provide the cytogenetics report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, blood or bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), and molecular tests as medically necessary.
The client’s pathologist must provide the flow cytometry report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
The client’s pathologist must provide the morphology report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
Includes COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
Includes COMPASS® consultation report, clinical pathology evaluation, blood morphology (up to 10 cytochemical stains), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.
CONTACT US
Genoptix, a NeoGenomics Company
2131 Faraday Ave
Carlsbad, CA 92008
Phone: +1.760.268.6200
Fax: +1.760.268.6201
Client Services
Phone: +1.800.755.1605
Fax: +1.888.755.1604
Email: clientservices@genoptix.com
Medical Director: Derek Lyle, MD
Recent News
NeoGenomics Completes Acquisition of Genoptix, Inc.December 10, 2018 - 9:00 am- NeoGenomics Signs Definitive Agreement to Acquire GenoptixOctober 23, 2018 - 9:00 am
- Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna® (nilotinib)September 4, 2018 - 8:30 am
HOURS OF OPERATION
Our lab is open six days a week:
5:00am to 6:00pm PT Mon-Fri
7:00am to 3:30pm PT Saturday
For after-hours assistance, your call
will be connected with an on-duty
Client Services Representative.
